Results 151 to 160 of about 97,287 (310)

Calciprotein particle‐induced calcium overload triggers mitochondrial dysfunction in endothelial cells

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Calciprotein particles (CPPs) are small calcium‐ and phosphate‐containing nanoaggregates associated with the development of vascular disease (CVD) in chronic kidney disease (CKD). Previously, we have shown that CPPs induce endothelial cell (EC) dysfunction, possibly contributing to CVD in CKD, but the underlying molecular ...
Lian Feenstra   +9 more
wiley   +1 more source

SOME ASPECTS OF VIRULENCE OF ISONIAZID-RESISTANT TUBERCLE BACILLI

open access: bronze, 1955
KOOMI KANAI   +3 more
openalex   +2 more sources

Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism

open access: yesInternational Journal of Cancer, Volume 157, Issue 10, Page 1991-2003, 15 November 2025.
Abstract Abnormal epigenetic patterns are crucial for the progression of metabolic‐associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC) development. Recent research focused on the interplay between epigenetics and altered metabolic pathways in HCC from MASLD, suggesting that the reversibility of epigenetic changes offers ...
Chiara Aiello   +7 more
wiley   +1 more source

Isoniazid and loss of memory. [PDF]

open access: bronze, 1969
P. Zander Olsen, K Tørning
openalex   +1 more source

Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study

open access: yesAnnals of Neurology, Volume 98, Issue 5, Page 951-966, November 2025.
Objective Landau–Kleffner syndrome (LKS), is a rare, poorly‐understood epileptic encephalopathy with spike–wave activation in sleep associated with mutations in GRIN2A, encoding the N‐Methyl‐D‐Aspartate receptor (NMDAR) GluN2A subunit. Physicians rely on empirical treatments, with scarce information on treatment efficacy and outcomes.
Adeline Ngoh   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy